Integer Holdings Corp ITGR revenue by segment, product and geography
In its fiscal year ending 2025-12-31, Integer Holdings Corp reported revenue across 1 business segments; the largest, Reportable Segment, was $1.85B, 100.0% of the filed sum (+8.0% against the prior period in the same filing).
Reported segment mix
figures as filed · share of the filed sum · change vs the prior period in the same filing- Reportable Segment$1.85B100.0%+8.0% yoy
Members sum to the consolidated $1.85B for this period.
- Reportable Segment$221M100.0%+6.3% yoy
Members sum to the consolidated $221M for this period.
- Cardio And Vascular$1.11B59.7%+16.6% yoy
- Cardiac Rhythm Management Neuromodulation$669M36.1%+1.2% yoy
- Other Markets$77.8M4.2%-26.9% yoy
Members sum to the consolidated $1.85B for this period.
- United States$980M52.9%+4.4% yoy
- Rest of world$470M25.3%+8.8% yoy
- CR$174M9.4%+39.2% yoy
- PR$131M7.1%-4.2% yoy
- Ireland$99.2M5.3%+17.5% yoy
Members sum to the consolidated $1.85B for this period.
- Cardio And Vascular$262M59.5%+1.1% yoy
- Cardiac Rhythm Management Neuromodulation$168M38.3%+4.9% yoy
- Other Markets$9.58M2.2%-47.3% yoy
Change is against the same quarter a year earlier, as reported in the same 10-Q.
Source: SEC DERA Financial Statement and Notes data sets. Dimensional XBRL facts on the business-segment, product/service and geographic axes; the engine keeps the accession of every figure. Descriptive and educational, not advice.
About these figures
Companies tag segment, product and geographic revenue as dimensional XBRL facts in their 10-K and 10-Q filings. The SEC publishes those facts in its DERA Financial Statement and Notes data sets; TrendNalysis ingests each monthly file and serves the facts exactly as filed, keyed to the accession of the filing. Shares are of the filed sum. Where a filer tags more than one breakdown on one axis, the sum exceeds consolidated revenue and no shares are computed; where the members do not add up to the consolidated figure, the residual is stated rather than hidden. Missing is never zero.
Descriptive and educational; not investment advice. Methodology and data lineage.